PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy

Objectives:  To identify the prognostic factors and determine which pT3 prostate cancer patients can be safely followed up after surgery without any adjuvant treatment. Methods:  A retrospective review was carried out on 106 patients with pT3 prostate cancer. All preoperative and postoperative param...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of urology 2009-12, Vol.16 (12), p.941-946
Hauptverfasser: Inagaki, Takeshi, Kohjimoto, Yasuo, Nishizawa, Satoshi, Kuramoto, Tomomi, Nanpo, Yoshihito, Fujii, Reona, Matsumura, Nagahide, Shintani, Yasuyo, Uekado, Yasunari, Hara, Isao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives:  To identify the prognostic factors and determine which pT3 prostate cancer patients can be safely followed up after surgery without any adjuvant treatment. Methods:  A retrospective review was carried out on 106 patients with pT3 prostate cancer. All preoperative and postoperative parameters, including the postoperative serum prostate‐specific antigen (PSA) level at 3 months after surgery, were assessed by univariate and multivariate analyses. Results:  Mean follow‐up period was 18 months. The overall biochemical recurrence‐free rate was 53.7% and 34.1% at 12 and 36 months, respectively. On univariate analysis, all preoperative clinical factors were significantly correlated with biochemical progression. On multivariate analysis, pathological Gleason score, pathological stage and postoperative PSA were significant predictors. Among those with undetectable PSA after surgery, 38 patients (88.4% of 43) did not have disease progression during the follow‐up period. On the other hand, of the 27 patients with detectable PSA that was not defined as progressive (range 0.01–0.20), 22 (81.5%) had biochemical disease progression. The progression free probability was significantly different between these two groups (P‐value 
ISSN:0919-8172
1442-2042
DOI:10.1111/j.1442-2042.2009.02401.x